Use of l-carnitine for the treatment of cardiovascular diseases
AssigneeSigma-Tau Industrie Farmaceutiche Riunite S.p.A.
InventorAleardo Koverech
Life of this patent
Estimating the term…
Abstract
The use of L-carnitine or one of its pharmaceutically acceptable salts is described for the preparation of a medicine useful for reducing the number of deaths caused by acute myocardial infarction and for improving the short-and-long-term prognosis in the patients treated with it, in which L-carnitine is administered parenterally within the first few hours of onset of the symptoms of acute myocardial infarction at an initial dose of 9 grams a day for 5 days, after which the treatment is continued at a dose of 4 grams a day by the enteral route.
Claims17
A method of reducing the number of deaths caused by acute myocardial infarction and for improving the short-and long-term prognosis in the patients treated with it, comprising intravenously administering L-carnitine or one of its pharmaceutically acceptable salts within the first few hours of onset of the symptoms of acute myocardial infarction at an initial dose of 9 grams a day for 5 days, after which the treatment is continued as a dose of 4 grams a day by mouth.
A method of reducing the number of deaths caused by acute myocardial infarction and for improving the short and long-term prognosis in the patients treated, comprising intravenously administering L-carnitine or one of its pharmaceutically acceptable salts within the first few hours of onset of the symptoms of acute myocardial infarction at an initial dose of 9 grams a day for 5 days, after which the treatment is continued at a dose of 4 grams a day by mouth in combination with one or more drugs, and/or mechanical and/or surgical techniques, which alone would fail to reduce the number of deaths in infarct victims.
Dependencies are inferred from the claim text.